Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 25 peer-reviewed journal articles Updated
Urology · Recurrent Urinary Tract Infection

Standard of Care Treatment: Recurrent UTIs (rUTI)

At a Glance

Recurrent UTI care combines culture-guided treatment with prevention: adequate fluids, vaginal estrogen for peri- and postmenopausal women, methenamine, or carefully selected postcoital or continuous antibiotics. The best plan balances fewer infections with fewer side effects and less resistance.

Managing Recurrent Urinary Tract Infections (rUTI) requires a shift from simply treating “one-off” infections to building a long-term prevention strategy. This evidence mainly concerns recurrent uncomplicated cystitis in appropriately selected adults, often women. (If you are pregnant, male, immunocompromised, or have recurrent kidney infections or persistent hematuria, you require different or more urgent evaluation.) Modern medical guidelines define rUTI as having at least two infections in six months or three in a year, with at least one (and ideally all) confirmed by a laboratory urine culture [1][2].

The goal of treatment is to reduce the frequency of infections while minimizing the use of antibiotics to prevent side effects and bacterial resistance [3][4].

Step 1: Treatment of the Acute “Flare”

When you have active symptoms, your doctor will ideally use a culture-directed approach. This means choosing an antibiotic based on what grew in your previous tests or what is currently growing in your lab sample [5][6].

For patients who can reliably recognize their symptoms and have a history of predictable, uncomplicated infections, a self-start therapy plan may be an option. In this scenario, your doctor provides a “standing” prescription that you fill and begin taking as soon as symptoms start. You should still provide a urine sample to the lab before taking the first pill, and this is not appropriate if you have systemic symptoms like fever or flank pain [5][7].

Step 2: Non-Antibiotic Prevention

Before moving to long-term antibiotics, current guidelines emphasize “antibiotic-sparing” strategies:

  • Vaginal Estrogen: For peri- and postmenopausal women, this is one of the most effective tools available. It helps restore the healthy bacteria (Lactobacillus) in the vaginal area that protect against UTI-causing germs [8][9]. Studies show it can reduce the risk of recurrence by over 50% compared to a placebo [10]. It must be applied locally (as a cream, ring, or tablet) rather than taken as an oral pill to be effective for this purpose [2][11].
  • Methenamine Hippurate: This is a medication that turns into a mild antiseptic in the urine, making it harder for bacteria to grow [12]. A major 12-month trial found it was “non-inferior” to daily antibiotics, meaning it worked nearly as well without the same risk of creating “superbugs” [12][13]. It requires attention to renal and hepatic function, and routine Vitamin C supplementation should not be used without prescriber advice due to kidney stone risks.
  • Behavioral Changes: Simply increasing your daily water intake to reasonable levels can significantly reduce your risk of a new infection, especially if you normally drink very little [2][3].

Step 3: Supplements (Cranberry and D-Mannose)

The evidence for popular supplements is mixed, and they are often considered “preference-sensitive” options:

  • Cranberry: Large reviews show that cranberry products (specifically those containing proanthocyanidins or PACs) can have a modest effect in preventing UTIs in some women [14][15]. However, the dose and formulation vary widely between products [16].
  • D-Mannose: While earlier small studies were promising, a large 2024 trial found that D-mannose did not significantly reduce the number of UTIs compared to a placebo [17][18]. It is currently not routinely recommended as a reliable prevention strategy [17].

Step 4: Antibiotic Prophylaxis

If non-antibiotic measures are not enough, your doctor may discuss antibiotic prophylaxis (taking a low dose of medicine to prevent symptomatic recurrences). Antibiotics should not be used to treat asymptomatic bacteriuria in most nonpregnant adults. There are two main ways to do this:

  1. Postcoital Prophylaxis: If your infections are clearly triggered by sexual activity, you take a single low dose of an antibiotic (like nitrofurantoin or cephalexin) only after sex [19][20]. This is often just as effective as daily dosing but involves much less medication overall [20].
  2. Continuous Prophylaxis: You take a low-dose antibiotic every night [21]. While very effective at stopping UTIs, this approach carries a risk of side effects like nausea, yeast infections, or C. difficile (a severe gut infection) [22][23]. Specific agents like nitrofurantoin also carry risks of pulmonary and hepatic toxicity with long-term use. It also increases the likelihood that any future infection you do get will be resistant to that antibiotic [24][25].

Doctors usually trial these regimens with a reassessment at 3 to 6 months before stopping to see if the cycle of infections has been broken [13][5].

Common questions in this guide

How many UTIs count as a recurrent UTI?
Recurrent UTI usually means at least two infections within six months or at least three within one year. A urine culture should confirm at least one episode, and ideally each infection, before a long-term prevention plan is chosen. This page focuses on recurrent uncomplicated bladder infections in appropriately selected adults.
Should I get a urine culture before taking antibiotics for a recurrent UTI?
When possible, provide a urine sample before the first antibiotic dose so treatment can target the bacteria causing the infection. A clinician may prescribe self-start treatment for people with predictable, uncomplicated episodes, but fever or flank pain requires prompt evaluation rather than relying on a standing prescription.
What non-antibiotic options help prevent recurrent UTIs?
Prevention may include local vaginal estrogen, methenamine hippurate, a reasonable increase in water intake, or cranberry products containing protective compounds called proanthocyanidins. Vaginal estrogen is particularly useful for peri- and postmenopausal women, while cranberry may offer only modest benefit and products vary. A large recent trial did not find D-mannose reliably helpful, so it is not routinely recommended.
Can vaginal estrogen reduce recurrent UTIs after menopause?
Local vaginal estrogen, used as a cream, ring, or tablet, can restore protective bacteria in the vaginal area and lower recurrent UTI risk for peri- and postmenopausal women. Oral estrogen is not used for this UTI-prevention purpose. Ask a clinician whether it is appropriate for your medical history.
Is methenamine as effective as daily antibiotics for UTI prevention?
Methenamine hippurate worked nearly as well as daily antibiotics in a major 12-month study while avoiding some antibiotic-resistance concerns. It may not be suitable for everyone, so a clinician should review kidney and liver function before prescribing it. Do not add routine vitamin C without medical advice because of possible kidney stone risk.
What is the difference between taking an antibiotic after sex and taking one every day?
If sexual activity clearly triggers your UTIs, a single prescribed dose after sex may prevent recurrences as effectively as daily low-dose treatment while using less antibiotic. Daily prophylaxis may be considered when episodes are not linked to sex, but it has risks such as side effects, yeast infection, C. difficile infection, and resistance. Your clinician should help select and reassess the plan.
How long should I try preventive antibiotics for recurrent UTIs?
Clinicians commonly reassess continuous or postcoital prophylaxis after about three to six months to decide whether it should continue or stop. Long-term antibiotics can cause nausea, yeast infections, C. difficile infection, antibiotic resistance, and, with some drugs such as nitrofurantoin, lung or liver toxicity. The timing and monitoring should be individualized.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Is my kidney function (creatinine clearance) high enough for methenamine hippurate to be safe and effective?
  2. 2.Given my age and symptoms, would a prescription for vaginal estrogen cream or a ring be a good first-line prevention for me?
  3. 3.If I choose to try a cranberry product, which specific formulation or 'proanthocyanidin' (PAC) dose do you recommend based on recent studies?
  4. 4.Can we set up a plan for 'self-start' antibiotics so I can begin treatment quickly while still sending a culture to the lab?
  5. 5.What are the specific risks for me if I take low-dose antibiotics daily for six months, such as yeast infections or C. difficile?
  6. 6.Since my UTIs usually happen after sex, would a single dose of an antibiotic after activity be just as effective as taking one every day?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (25)
  1. 1

    State-of-the-Art Review: Recurrent Uncomplicated Urinary Tract Infections in Women.

    Advani SD, Thaden JT, Perez R, et al.

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2025; (80(3)):e31-e42 doi:10.1093/cid/ciae653.

    PMID: 40095960
  2. 2

    The Diagnosis, Treatment, and Prevention of Recurrent Urinary Tract Infection.

    Schmiemann G, Kranz J, Mandraka F, et al.

    Deutsches Arzteblatt international 2024; (121(11)):373-382.

    PMID: 38686602
  3. 3

    Update to the management of recurrent urinary tract infections in women aged 16 years and older.

    Sanyaolu L, Ahmed H, Santer M, et al.

    Drug and therapeutics bulletin 2026; (64(8)):116-125 doi:10.1136/dtb.2025.000042.

    PMID: 42044997
  4. 4

    New paradigms in the management of recurrent urinary tract infections.

    Taich L, Zhao H, Cordero C, Anger JT

    Current opinion in urology 2020; (30(6)):833-837 doi:10.1097/MOU.0000000000000823.

    PMID: 32941258
  5. 5

    Joint report of SBI (Brazilian Society of Infectious Diseases), FEBRASGO (Brazilian Federation of Gynecology and Obstetrics Associations), SBU (Brazilian Society of Urology) and SBPC/ML (Brazilian Society of Clinical Pathology/Laboratory Medicine): recommendations for the clinical management of lower urinary tract infections in pregnant and non-pregnant women.

    de Rossi P, Cimerman S, Truzzi JC, et al.

    The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 2020; (24(2)):110-119 doi:10.1016/j.bjid.2020.04.002.

    PMID: 32360431
  6. 6

    The 2017 Update of the German Clinical Guideline on Epidemiology, Diagnostics, Therapy, Prevention, and Management of Uncomplicated Urinary Tract Infections in Adult Patients. Part II: Therapy and Prevention.

    Kranz J, Schmidt S, Lebert C, et al.

    Urologia internationalis 2018; (100(3)):271-278 doi:10.1159/000487645.

    PMID: 29539622
  7. 7

    No. 250-Recurrent Urinary Tract Infection.

    Epp A, Larochelle A

    Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC 2017; (39(10)):e422-e431 doi:10.1016/j.jogc.2017.08.017.

    PMID: 28935065
  8. 8

    Vaginal Estrogen for the Prevention of Recurrent Urinary Tract Infection in Postmenopausal Women: A Randomized Clinical Trial.

    Ferrante KL, Wasenda EJ, Jung CE, et al.

    Female pelvic medicine & reconstructive surgery 2021; (27(2)):112-117 doi:10.1097/SPV.0000000000000749.

    PMID: 31232721
  9. 9

    Characterizing the role of the urobiome in the pathogenesis of recurrent urinary tract infections (rUTIs): a systematic review.

    Sheiber J, Duque A, Ranjan A, et al.

    International urology and nephrology 2026; doi:10.1007/s11255-026-05317-8.

    PMID: 42573928
  10. 10

    Estrogen for the prevention of recurrent urinary tract infections in postmenopausal women: a meta-analysis of randomized controlled trials.

    Chen YY, Su TH, Lau HH

    International urogynecology journal 2021; (32(1)):17-25 doi:10.1007/s00192-020-04397-z.

    PMID: 32564121
  11. 11

    Vaginal Estrogen for Urinary Tract Infection Prevention: A Narrative Review of Evidence, Guidelines, and Regulatory Gaps.

    Ghasoub R, Mackay W, Shepherd A

    Gynecologic and obstetric investigation 2026; 1-9 doi:10.1159/000553344.

    PMID: 42378201
  12. 12

    Alternative to prophylactic antibiotics for the treatment of recurrent urinary tract infections in women: multicentre, open label, randomised, non-inferiority trial.

    Harding C, Mossop H, Homer T, et al.

    BMJ (Clinical research ed.) 2022; (376()):e068229 doi:10.1136/bmj-2021-0068229.

    PMID: 35264408
  13. 13

    Methenamine hippurate compared with antibiotic prophylaxis to prevent recurrent urinary tract infections in women: the ALTAR non-inferiority RCT.

    Harding C, Chadwick T, Homer T, et al.

    Health technology assessment (Winchester, England) 2022; (26(23)):1-172 doi:10.3310/QOIZ6538.

    PMID: 35535708
  14. 14

    Are High Proanthocyanidins Key to Cranberry Efficacy in the Prevention of Recurrent Urinary Tract Infection?

    Vostalova J, Vidlar A, Simanek V, et al.

    Phytotherapy research : PTR 2015; (29(10)):1559-67 doi:10.1002/ptr.5427.

    PMID: 26268913
  15. 15

    Nonantibiotic prophylaxis for urinary tract infections: a network meta-analysis of randomized controlled trials.

    Han Z, Yi X, Li J, et al.

    Infection 2025; (53(2)):535-546 doi:10.1007/s15010-024-02357-z.

    PMID: 39095666
  16. 16

    High dose versus low dose standardized cranberry proanthocyanidin extract for the prevention of recurrent urinary tract infection in healthy women: a double-blind randomized controlled trial.

    Babar A, Moore L, Leblanc V, et al.

    BMC urology 2021; (21(1)):44 doi:10.1186/s12894-021-00811-w.

    PMID: 33757474
  17. 17

    d-Mannose for Prevention of Recurrent Urinary Tract Infection Among Women: A Randomized Clinical Trial.

    Hayward G, Mort S, Hay AD, et al.

    JAMA internal medicine 2024; (184(6)):619-628 doi:10.1001/jamainternmed.2024.0264.

    PMID: 38587819
  18. 18

    Efficacy of D-mannose as prophylaxis of recurrent urinary tract infection: a systematic review and meta-analysis of randomized controlled trials.

    Vargas CEF, Mutarelli A, Menegardo LG, et al.

    Jornal brasileiro de nefrologia 2025; (47(4)):e20250169 doi:10.1590/2175-8239-JBN-2025-0169en.

    PMID: 41004704
  19. 19

    Treatment and Prevention of Recurrent Lower Urinary Tract Infections in Women: A Rapid Review with Practice Recommendations.

    Smith AL, Brown J, Wyman JF, et al.

    The Journal of urology 2018; (200(6)):1174-1191 doi:10.1016/j.juro.2018.04.088.

    PMID: 29940246
  20. 20

    Antibiotics for Preventing Recurrent Urinary Tract Infection: Systematic Review and Meta-analysis.

    Jent P, Berger J, Kuhn A, et al.

    Open forum infectious diseases 2022; (9(7)):ofac327 doi:10.1093/ofid/ofac327.

    PMID: 35899289
  21. 21

    Latin American consensus on uncomplicated recurrent urinary tract infection-2018.

    Haddad JM, Ubertazzi E, Cabrera OS, et al.

    International urogynecology journal 2020; (31(1)):35-44 doi:10.1007/s00192-019-04079-5.

    PMID: 31494690
  22. 22

    The Benefits and Harms of Antibiotic Prophylaxis for Urinary Tract Infection in Older Adults.

    Langford BJ, Brown KA, Diong C, et al.

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2021; (73(3)):e782-e791 doi:10.1093/cid/ciab116.

    PMID: 33595621
  23. 23

    Nitrofurantoin vs other prophylactic agents in reducing recurrent urinary tract infections in adult women: a systematic review and meta-analysis.

    Price JR, Guran LA, Gregory WT, McDonagh MS

    American journal of obstetrics and gynecology 2016; (215(5)):548-560 doi:10.1016/j.ajog.2016.07.040.

    PMID: 27457111
  24. 24

    Uropathogen Resistance and Antibiotic Prophylaxis: A Meta-analysis.

    Selekman RE, Shapiro DJ, Boscardin J, et al.

    Pediatrics 2018; (142(1)) doi:10.1542/peds.2018-0119.

    PMID: 29954832
  25. 25

    Continuous low-dose antibiotic prophylaxis for adults with repeated urinary tract infections (AnTIC): a randomised, open-label trial.

    Fisher H, Oluboyede Y, Chadwick T, et al.

    The Lancet. Infectious diseases 2018; (18(9)):957-968 doi:10.1016/S1473-3099(18)30279-2.

    PMID: 30037647

This page explains recurrent UTI treatment and prevention for informational purposes only and does not constitute medical advice. A clinician should confirm the diagnosis and tailor antibiotics or other options to your urine culture, kidney function, pregnancy status, and overall health.

Get notified when new evidence is published on chronic cystitis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.